Company profile: Tuhura Biosciences
1.1 - Company Overview
Company description
- Provider of phase 3 registration-stage immuno-oncology therapies, including personalized cancer vaccines (IFx-2.0 intratumoral pDNA expressing a bacterial protein; IFx-3.0 IV emm55 mRNA targeting CD22 for blood-related cancers) and MDSC-targeting bi-functional antibody drug conjugates (TBS-2025 Nal-anti TIGIT) to modulate immunosuppression, deliver a checkpoint inhibitor or T cell activator, and counter resistance to immunotherapies.
Products and services
- IFx-2.0: A personalized, pDNA-based vaccine injecting a small-dose of pDNA intratumorally to express bacterial protein on tumors, activating innate immunity and potentially overcoming resistance to checkpoint inhibitors
- Bi-Functional Antibody Drug Conjugates (ADCs): ADC-based components that target Myeloid Derived Suppressor Cells to inhibit immunosuppression while delivering checkpoint inhibitors or T-cell activators, preventing T-cell exhaustion and resistance to immunotherapies
- TBS-2025: Nal – anti TIGIT: A Delta-receptor-targeted bi-functional antibody-drug conjugate that modulates MDSC immunosuppression and carries an anti-TIGIT antibody for treating high-risk myelodysplasia
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tuhura Biosciences
Gennao Bio
HQ: United States
Website
- Description: Provider of genetic medicines developing targeted nucleic acid therapeutics for muscle diseases, featuring GMAB, a non-viral, cell-penetrating antibody technology that delivers nucleic acid payloads into cells targeting cancer and skeletal muscle disorders, and GMAB ADC for solid tumors, an antibody-drug conjugate demonstrated in preclinical studies to deliver cytotoxic drugs directly to tumor cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gennao Bio company profile →
Dragonfly Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage immunotherapies harnessing the innate and adaptive immune systems. Offers the TriNKET platform for tri-specific immune engagers and a CYTOKINE platform for cytokine-based therapies for cancer and other diseases. Pipeline includes DF1001 (HER2, solid tumors), DF9001 (EGFR, solid tumors), DF6215 (IL-2, advanced solid tumors), and DF6002 (IL-12, extended half-life) for cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dragonfly Therapeutics company profile →
MetaStat
HQ: United States
Website
- Description: Provider of diagnostic technologies and therapeutics for the early detection and treatment of systemic metastasis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MetaStat company profile →
TME Pharma
HQ: Germany
Website
- Description: Provider of biostable aptamer therapeutics based on mirror image nucleic acids, including NOX-A12 to enhance anti-cancer treatments in glioblastoma and pancreatic cancer and NOX-E36 to improve tumor immune response. Operates GLORIA, OPERA & OPTIMUS trials, and pursues collaborations, including a strategic alliance with Pfizer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TME Pharma company profile →
Cellcentric
HQ: United Kingdom
Website
- Description: Provider of clinical-stage biotechnology therapies targeting p300/CBP inhibition to treat specific cancers, particularly solid tumors; developing the oral drug Inobrodib, currently in Phase I/II trials, with potential utility in non-small cell lung, breast, colon cancers and multiple myeloma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellcentric company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tuhura Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tuhura Biosciences
2.2 - Growth funds investing in similar companies to Tuhura Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tuhura Biosciences
4.2 - Public trading comparable groups for Tuhura Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →